Loading
MB-105 is an experimental autologous CAR T-cell therapy from March Biosciences, in phase 2 trials for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia.
MB-105 (CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)) is an autologous CAR T-cell therapy from March Biosciences, with Baylor College of Medicine as partner. Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing. Its furthest stage is phase 2, for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia. ClinicalTrials.gov registers it in 2 studies linked below. Registry NCT06534060 phase 2 recruiting; long-term follow-up NCT07340814 not yet recruiting. Whether it works in people has not been established unless a trial below reports it.
Autologous T cells engineered to express a CD5-directed chimeric antigen receptor; the company says its CAR design resists the CAR T cells killing each other during manufacture without extra gene editing.
1.MB-105 slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MB-105" OR ABSTRACT:"MB-105" OR TITLE:"CD5.CAR/28zeta CAR T cells Baylor phase 1, name used in NCT03081910" OR ABSTRACT:"CD5.CAR/28zeta CAR T cells Baylor phase 1, name used in NCT03081910") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MB-105, not a curated reading list.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/